89bio Stock Price, News & Analysis (NASDAQ:ETNB)

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ETNB shares.
View ETNB analyst ratings or view top-rated stocks.

6 brokers have issued 12-month target prices for 89bio's stock. Their ETNB share price targets range from $24.00 to $50.00. On average, they expect the company's share price to reach $32.89 in the next twelve months. This suggests a possible upside of 233.6% from the stock's current price.
View analysts price targets for ETNB or view top-rated stocks among Wall Street analysts.

89bio's stock was trading at $12.73 at the beginning of the year. Since then, ETNB stock has decreased by 22.5% and is now trading at $9.86.
View the best growth stocks for 2023 here.

89bio saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 6,040,000 shares, an increase of 11.2% from the October 31st total of 5,430,000 shares. Based on an average daily volume of 1,550,000 shares, the days-to-cover ratio is currently 3.9 days.
View 89bio's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, March 8th 2024.
View our ETNB earnings forecast.

89bio, Inc. (NASDAQ:ETNB) issued its quarterly earnings data on Wednesday, November, 8th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.08. The firm earned $1 million during the quarter, compared to analyst estimates of $0.38 million. 89bio's revenue for the quarter was up .0% on a year-over-year basis.

ETFs with the largest weight of 89bio (NASDAQ:ETNB) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Invesco DWA SmallCap Momentum ETF (DWAS), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC) and Harbor Health Care ETF (MEDI).iShares Micro-Cap ETF (IWC).

Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Cisco Systems (CSCO), Pfizer (PFE), CVS Health (CVS), RTX (RTX), Alibaba Group (BABA), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ) and Thermo Fisher Scientific (TMO).

(ETNB) raised $70 million in an IPO on the week of November 11th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

89bio's stock is owned by many different retail and institutional investors. Top institutional investors include Federated Hermes Inc. (2.82%), Adage Capital Partners GP L.L.C. (2.25%), Braidwell LP (2.11%), Westfield Capital Management Co. LP (1.74%), Laurion Capital Management LP (1.59%) and Eagle Asset Management Inc. (0.94%). Insiders that own company stock include Edward Morrow Atkinson III, Gregory Grunberg, Kathleen Laporte, Michael R Hayden, Ollin B Sykes, Orbimed Advisors Llc, Quoc Le-Nguyen, Ra Capital Management, LP, Ram Waisbourd, Rohan Palekar and Ryan Martins.
View institutional ownership trends.

Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.